Abstracts tagged "anti-TNF therapy and registry"

Abstract Number: 1552 • 2017 ACR/ARHP Annual Meeting
Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There are limited data regarding persistency of TNF inhibitor (TNFi) therapies in patients with ankylosing spondylitis (AS) treated in real-world clinical practice. The objective…
Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…
Abstract Number: 583 • 2014 ACR/ARHP Annual Meeting
What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction
Proton Rahman¹, Michel Zummer², Wojciech Olszynski³, Majed Khraishi⁴, Dalton Sholter⁵, Rafat Faraawi⁶, William Bensen⁷, Milton Baker⁸, Andrew Chow⁹, Julie Vaillancourt¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J Lehman¹², Susan Otawa¹² and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Université de Montréal, Montreal, QC, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵University of Alberta, Edmonton, AB, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose Despite the importance of the Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing patient-reported functional status and disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].